|
Post by bradleysbest on Nov 16, 2014 21:18:55 GMT -5
Good find KC! This is just the beginning....
|
|
|
Post by Chris-C on Nov 18, 2014 1:26:51 GMT -5
Comments from Nate Pile on Mannkind in the (November) blog of his much followed Nate's Notes Investors Newsletter to which I subscribe:
Another MannKind Card About To Be Flipped Over
In this article, Pile reports that MannKind’s partner Sanofi (SNY – $46.68) will be holding a “New Medicines Day” seminar that will be webcast live for investors starting at 8:30am Eastern on Thursday, November 20th.
Given that Afrezza is on the list of new products that Sanofi plans to discuss, he thinks that what is said (or not said) about the product will finally shed some light for us on the question about how Sanofi is actually viewing the partnership.If Afrezza only gets a small or negligible mention, Pile believes the stock price will suffer (perhaps back into the mid-$4s ). But, if Afrezza gets a fair amount of discussion, he thinks the stock will continue trading sideways or slightly higher while observers await Afrezza sales to start early next year...
However, If Sanofi shows that it does, in fact, plan on making the rapid-acting nature of Afrezza a key selling point when it comes to pitching its line-up of complementary diabetes drugs, he thinks there is an above-average chance that at least a handful of short sellers will start to cover adding fuel to the fire that he believes will be lit for new investors as they start to finally understand that Afrezza may, in fact, represent a significant paradigm shift in the treatment of diabetes.
The article goes on to say that Nate continues to believe that MNKD has one of the best risk reward ratios he has seen in a biotech investing opportunity in quite some time. And this assessment is just for Afrezza, and does not include the unknown value of Technosphere.
Chris_C
|
|
|
Post by otherottawaguy on Nov 18, 2014 9:03:49 GMT -5
from the magazine article:
WITH 40 PERCENT OF AMERICANS PREDICTED TO DEVELOP TYPE 2 WITH 40 PERCENT OF AMERICANS PREDICTED TO DEVELOP TYPE 2
diabetes in their lifetime, according to the Centers for Disease Control and Prevention’s latest fi ndings, it’s no wonder scientists are working around the clock to treat, manage and possibly even reverse the condition. Here’s a roundup of the latest breakthroughs. No more needles! This summer, the U.S. Food and Drug Administration (FDA) approved Afrezza, a rapid-acting inhaled insulin for adults with Type 1 and Type 2 diabetes, which is expected to hit the market in early 2015. The whistle-sized inhaler is used about 20 minutes prior to eating. Peak insulin levels are achieved within 15 minutes of the puff , compared to about an hour with traditional injected insulin. “This new delivery system is absorbed through the lungs, so it begins to work very quickly,” says Robert Ratner, MD, the American Diabetes Association’s (ADA) chief medical offi cer. “You can literally take it with the fi rst bite of the meal. It’s also out of the system faster, so there is less risk of low blood sugar.”
|
|
|
Post by brentie on Nov 18, 2014 9:30:36 GMT -5
Unless things have changed since Chris Vierbacher was shown the door, I think they will make it a key selling point. Here's what he said at their last earnings call..... "So, very strong R&D progress. We also on Slide 14 have brought in a new medicine in diabetes called Afrezza and I think Afrezza obviously, I know you an awful lot of people I think we have got Exubera, we know Exubera Sanofi sold it to Pfizer for a nice chunk of money. But I think because we knew of Exubera, we also were able to I think assess why Afrezza is different. One of the first if you see it immediately in the picture is the small elegant device that is there, and the other is that this has a PK profile that really can mimic the natural prandial insulin response. They are pretty quick on and a pretty quick off, very easy to take. We are not necessarily seeing it just to replace injection but we know is that there is often a lost decade that many specialists refer to and this is a time it often takes for people to move from oral therapies which have really stopped working and transfer to an injectible product. So we think actually that, even as an add on to oral could be an interesting way to get people on insulin therapy a little bit faster." seekingalpha.com/article/2606755-sanofis-sny-ceo-chris-viehbacher-on-q3-2014-results-earnings-call-transcript?find=afrezza&all=false (slide 14)
|
|
|
Post by mannmade on Nov 18, 2014 12:58:42 GMT -5
www.notwallstreet.com/another-mannkind-card-flipped-111814/About Education Media Appearances Performance Sample Issue Contact SIGN-UP Another MannKind Card About To Be Flipped 11/18/14 ***The following is excerpted from the November issue (11/14/14) of Nate’s Notes that was published for subscribers last weekend*** “Take Two And Call Me In The Morning…” What a crazy past several weeks, eh?! If you recall, the market as a whole was starting to look especially weak as last month’s issue was going to press, and to make things even more interesting, for the first time in ages, one of the five major indices we use to gauge the health of the overall market (see Eyebrow Levels table below) had actually fallen below its one eyebrow level that very day. Not only had the SOX semiconductor index taken a dramatic turn for the worse that Friday (with some of our chip stocks down 8% or more in that trading session alone!), the other three non-biotech indices were also perilously close to flashing bearish signals for us… and consequently, in order to help everyone sleep more easily at night (along with the fact that I intentionally only make trades once a month based on what is going on at publishing time), I decided that we would “take two for flinching” by selling off roughly 20% of all of our chip positions even though our Eyebrow Levels table had not actually called for such action just yet. In hindsight (and as you can see in the performance table above), we obviously should have trusted our system 100% and left all our chips on the table (pun intended) rather than moving some cash to the sidelines after all! That being said, however, though we did receive the anticipated penalty of “two for flinching” (i.e. we let go of roughly 20% of each of our semiconductor positions at what essentially turned out to be “the bottom” of the sell-off), the good news is that a) the sales gave me (and hopefully you) some peace of mind that made it easier to ride out those nail-biting couple of days that took place right after the issue was published, and b) we still own 80% of those positions… and many of the stocks are already starting to hit new multi-year highs again. In addition, if you recall, as part of our game plan to “hedge” against the possibility that our decision to take two for flinching was premature, we also made the conscious decision to add to our positions in two of our favorite stocks, namely Apple and MannKind… and both of those stocks have been performing very well since then (in fact, it appears that our purchase of MannKind may turn out to have been made on THE low closing price for the downtrend). Now that the market is once again heading the right direction (and we have had a round of solid profit-taking to help shake out weak holders), you are encouraged to become as aggressive as you can comfortably be while still sleeping at night when it comes to putting your capital back to work (while also keeping in mind that the sorts of monthly returns that were just generated in the Aggressive Portfolio, for example, are not sustainable, and thus you should not get used to them!). Along these lines (and, as always, with the caveat that you should never own more of a stock than you would feel comfortable losing in its entirety), given how the stock has been acting lately (and how strongly I believe that you should own at least a small position in the stock ahead of the launch of Afrezza), I want to draw your attention to the MannKind story yet again ahead of what may prove to be one of the most important days yet for us as long-term investors. Another MannKind Card About To Be Flipped Over In case you were not aware, MannKind’s partner Sanofi (SNY – $46.68) will be holding a “New Medicines Day” seminar that will be webcast live for investors starting at 8:30am Eastern on Thursday, November 20th. Afrezza is definitely included on the list of new products in its pipeline that Sanofi plans on discussing in more detail, and I believe that what is said (or not said) about the product will finally shed some light for us on the question about how Sanofi is actually viewing the partnership. If it turns out that Afrezza only gets a small mention and/or the presenters seem to be going out of their way to avoid saying much about the product, I am afraid the stock price will likely suffer a bit (perhaps back into the mid-$4s if the silence is deafening?). However, if Afrezza gets a fair amount of “airtime” in the course of discussion, I believe the stock will likely continue trade sideways or slightly higher while we wait for Afrezza sales to actually start early next year… And if it turns out that Sanofi does, in fact, plan on making the rapid-acting nature of Afrezza a key selling point when it comes to pitching its line-up of complementary diabetes drugs to doctors, insurance companies, and patients, I believe there is an above-average chance that at least a handful of short sellers will finally see the handwriting on the wall, throw in the towel, and start to cover some of the 80+ million shares that are currently sold short (and this, in turn, ought to add fuel to the fire that I likewise believe will be lit for new investors as they start to get their heads around the possibility that Afrezza may, in fact, represent a significant paradigm shift in the treatment of diabetes after all). As it stands, I believe there are a great many folks on Wall Street who have been (and still are) looking at Afrezza as nothing more than Exubera 2.0, and, consequently, a very “inefficient market” has been created for the stock. In fact, if it turns out that Sanofi does give Afrezza a reasonably-sized spotlight in the center ring next week, I will go so far as to say that it may represent the most inefficient market I have seen develop around a story in the sector since I first started following biotech stocks a little over 25 years ago! With downside risk of $3-$4 if I am wrong, but upside potential of $30-$40 (or more!) if I am right, I really like the risk-reward ratio from current prices (and I hope you do too)! A Couple of Frequently Asked Questions Aside from questions about specific stocks, two of the other questions that I have been asked most often lately are “do you ever sell stocks?” and “do you ever recommend new stocks?” Both are great questions, and to help answer them for everyone else who is fairly new to the newsletter and may be wondering the same thing but hadn’t gotten around to asking yet, I thought I’d offer the following set of thoughts to help shed some light on the situation. In a nutshell, “yes” to both questions… however, since I take such a long-term view to investing in stocks (and have intentionally set up Nate’s Notes in a publishing format that reinforces this approach), the frequency of such events in the newsletter is probably significantly lower than it is for most investors (especially if they enjoy trading on a daily or weekly basis). And, while it is true that the approach we take in the newsletter can seem dull at times, I believe the newsletter’s track record speaks for itself*… and it also lends a great deal of credence to old adage “When is the best time to sell a great growth stock? Never!” Though I am quite pleased with the performance that has been generated by a sensible weighting of the basket of stocks we have been working with for the past several years (and especially the past 18 months), I will also be the first to admit that it might not be a bad idea to do a bit of spring cleaning in the months ahead… and this, in turn, will free up some space in the newsletter to make some new recommendations as well. That being said, you are encouraged to stick to the game plan that I try to cover to one degree or another each month, namely, to be working on averaging-in to positions over time, with an eye towards those stocks that a) seem most interesting to you, b) are showing decent relative strength, and c) are still trading below their buy limits. In addition, I want to remind newer subscribers that your job will be even easier if you always start with the much smaller list of stocks that are delineated as “first buys” in the table on page 1 of the “pretty version” of the newsletter (or in the downloadable spreadsheet of data available on the same page of the website)… and, of course, be sure to read the “how to get started” material that was published in the May 2013 issue of the Nate’s Notes (see the “New To The Newsletter?” section of either online version of this month’s issue for a link to that issue). *in case you were not aware, Nate’s Notes is currently ranked #1 for 10-year performance by The Hulbert Financial Digest (HFD)… and I am looking forward to seeing where the newsletter ranks when it finally becomes eligible for ranking on the list for 15-year returns in early 2015 (HFD did not start covering Nate’s Notes until early 2000). “Eyebrow Levels” (used to help us gauge the overall health of the market*) current one eyebrow two eyebrows DJIA 17,391 16,250 15,400 Nasdaq 4,631 4,200 3,900 S&P500 2,018 1,875 1,740 BTK 3,354 2,575 2,175 SOX 641 580 540 *As long as all five indices are trading above their “one eyebrow” levels, it is a sign that the current uptrend is still intact; however, if the indices start to dip below those levels, it will cause me to raise an eyebrow and wonder if the trend my be coming to an end… and if both eyebrows go up, it will mean that things are deteriorating in a hurry (and you should start looking for a “Special Alert” from me in your email box). Top Picks (for new money this month) All else being equal (i.e. you already own “pretty much everything” in the newsletter), my top picks for you this month are: Electronic Arts (EA) – the stock appears to be breaking out to the upside, and if history is any guide, the odds are in our favor when it comes to seeing further gains as part of the run. MannKind (MNKD) – IF Afrezza is given a fairly large spotlight at Sanofi’s upcoming “New Medicines Day,” the revelation could help propel the stock back above $7 in a hurry. Perry Ellis (PERY) – the stock continues to perform well for us, and as one our favorite mantras goes, “trends often go on for far longer than seems reasonable.” Outstanding Orders For the reasons discussed above and below, the Model (Aggressive) Portfolio will not make any sales this month but will purchase 100 (1,000) Electronic Arts, 100 (1,000) Luminex, 1,000 (25,000) MannKind, and 100 (1,000) Perry Ellis. We will use the closing prices on Monday, November 17th, for all transactions. **************************** MannKind While it is certainly far too early to declare the “post-approval downtrend” a thing of the past, I do take heart in the fact that not only did we get to add a few more shares to the Aggressive Portfolio right near the low of the move, it appears that the pendulum may finally be starting to swing back the other direction as well. As discussed above, I believe the story may be shaping up to be one of the most attractive risk-reward ratios I have seen my 25+ years of following biotech, and though the stock will still only be a moderately-sized position in the Model Portfolio after this month’s purchases, it is intentionally one of our largest in the aptly named Aggressive Portfolio. MNKD is now a strong buy under $7 and a buy under $10.
|
|
|
Post by babaoriley on Nov 18, 2014 13:05:11 GMT -5
Good article, mannmade, thanks for posting! How have you been?
|
|
|
Post by mannmade on Nov 18, 2014 18:53:27 GMT -5
Hey Baba, am great! and hope you are as well... Found the item below... funny enough while I do not think it will happen any time soon it seems to have a little traction among the chatter again... www.benzinga.com/trading-ideas/long-ideas/14/11/5019622/what-other-mergers-are-possible-after-the-halliburton-baker-hWhat Other Mergers Are Possible After The Halliburton-Baker Hughes Deal? Halliburton Company (NYSE: HAL) has officially merged with Baker Hughes Incorporated (NYSE: BHI). The deal is for a reported $34.6 billion and is projected to save the oil giants a combined two billion dollars in costs. Mad Money host Jim Cramer is on record saying that this deal should not be allowed due to the monopolistic situation it could create. Despite his displeasure with the merger, most analysts expect the deal to be allowed. This begs the question: What other mergers are possible after this mega deal? Sanofi SA and MannKind Corporation would be a natural fit. The two biotech companies are already linked together through the partnership agreement of MannKind's diabetes drug Afrezza. While this wouldn't be nearly the mega deal that Halliburton-Baker Hughes was, this would likely put a significant amount of weight behind a breakthrough diabetes treatment. Related Link: 12 Money Myths Just Debunked By Experts Apple Inc. or Samsung Electronics, meanwhile, and BlackBerry Ltd would provide the consumer electronics space with a significant upgrade in security. While Apple and Samsung keep beating each other up for market share, Blackberry's device sales have fallen off the map. However, Apple and Samsung have had problems with their systems being hacked while Blackberry's security is arguably second to none. Facebook Inc and Google Inc may seem absurd to the more astute investor, but consider the spaces both companies reside in. The two tech giants compete directly in online ads, search and social media, and are gearing up for the Internet provider arena as well. This merger might be a long ways off, but could significantly benefit both companies if they were to pursue this option. Posted-In: Baker Hughes Halliburton merger Halliburton mergerLong Ideas Trading Ideas © 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
|
|
|
Post by gwb on Nov 18, 2014 19:10:18 GMT -5
Long history, most of us know. Interesting the SA owner ( Rabbi ) wouldn't post on SA, probably because he gets money from CNBC .
seekingalpha.com/instablog/8236691-verticalview/3477865-the-dangers-of-naked-shorting-the-effects-it-has-on-biotech-stocks-like-mannkind-and-dendreon-and-the-financial-markets-u-s-economy-and-national-security
The Dangers Of Naked Shorting : The Effects It Has On Biotech Stocks Like Mannkind And Dendreon And The Financial Markets, U.S. Economy And National Security 3 comments Nov 18, 2014 4:11 PM | about stocks: MNKD, DNDN, NWBO, SNY, GTXI, FNMA, FMCC
Dendreon (DNDN) and Mannkind Corp (MNKD): Victims of Naked Shorting and Bear Raid Attacks over Several Years
Our newly formed group Stop Naked Shorting ( see our petition at thepetitionsite ) believes overwhelming evidence proves naked shorting causes unfair financial stress on publicly traded companies and in some instances delays important drug development and drugs from reaching the market. We also believe Jim Cramer and Adam Feuerstein of TheStreet.com have for years been colluding with short and naked short hedge funds and others by deliberately making slanted sometimes outright false lies about DNDN & MNKD and other companies, biotech stocks in particular. (DNDN excerpts below, for full story click title link )
Michael Milken, 60,000 Deaths, and the Story of Dendreon
"This story, like too many others, begins with Jim Cramer, the CNBC personality, making "a mistake."
On September 26, 2005, Cramer announced to his television audience the sad news (punctuated by funny sound effects - a clown horn, a crashing airplane) that Provenge, an experimental treatment for prostate cancer, had flopped. Thousands of end-stage patients had been pinning their hopes on Provenge, but according to Cramer the treatment had just been rejected by the Food & Drug Administration. It would never go to market.
This seemed odd, because Dendreon (NASDAQ: DNDN), the company developing Provenge, had not yet submitted an application for FDA approval. As everybody in the biotech investment community knew, Dendreon had, in fact, only recently completed Phase 3 clinical trials and probably would not face scrutiny from an FDA advisory panel for at least another year."
A more recent bear raid article was penned or should I say copied and pasted together by Adam Feuerstein the day after Dr. Mann and other officers had told investors and analyst in their earnings CC on Nov 3rd that MNKD and Sanofi (SNY) are both excited about manufacturing that is underway and planned marketing efforts. They made it very clear that the recent firing of Sanofi CEO was not a concern. ( Excerpts below, for full story go to)
Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership at TheStreet(Tue, Nov 4)
"MannKind (MNKD) used its quarterly conference call Monday night to tamp down any concerns about the firing of Sanofi (SNY) CEO Chris Viehbacher causing problems for the Afrezza diabetes partnership ahead of the expected first quarter 2015 launch.
Not everyone shares MannKind's confidence. Diabetic Investor's David Kliff, a longtime Afrezza skeptic, believes Viehbacher was the driving force behind the MannKind partnership and pushed the deal against the wishes of others at Sanofi who didn't want anything to do with the inhaled insulin device. Now that Viehbacher is out at Sanofi, Kliff says the Afrezza commercial launch might be in trouble even before it starts."
To those unfamiliar with Jim Cramer and Adam Feuerstein of the Street.com it is important to note that both of them have been MNKD bears and have executed strategically timed bear raids on DNDN & MNKD via Cramer's Mad Money segments and Feuerstein's slanted articles for years. Also Adam Feuerstein has been wrong about MNKD at almost every turn at least when it came to his slanted opinions that Afrezza would not receive Adcom Panel approval, strike 1 and FDA approval, strike 2 and on likelihood of MNKD ever finding a marketing partner, strike 3. One would think he would of moved on by now after MNKD landed marketing deal with Sanofi (SNY) the biggest insulin marketing company in the world but his bear raid hit pieces keep on coming.
Jim Cramer has been a bit more cleverly cautious in his approach to delivering his negative slants on MNKD. Perhaps his blatant lies about DNDN in 2005 has him a bit more careful how he minces his words and helps his hedge fund "smarter buddies " profit from their short / naked short positions. (For a full list of slanted MNKD articles see) TheStreet.com
It almost seems coordinated short & distort bear raid attacks on publicly traded companies has become a full time occupation and that they do not seem to have any fear of SEC doing much of anything about it. The organization C.R.E.W. recently alleged Adam Feuerstein of the Street.com was involved in aiding such institutions with short and distort tactics, offering up negative slanted articles in order to drive stock prices lower. ( see excerpts below , click link for full story )
CREW Requests SEC Investigate Manipulation of Drug Company ...
"Washington, D.C. - Citizens for Responsibility and Ethics in Washington (CREW) today requested the Securities and Exchange Commission (SEC) investigate possible illegal manipulation of stock prices in Northwest Biotherapeutics, (NWBO) a biotechnology company developing cancer treatment drugs. Strategically released blog posts by well-known biotech stock analyst and senior columnist for TheStreet.com Adam Feuerstein seem designed to cause the price of the company's stock to fall at times when short sellers were financially overexposed. CREW has asked the SEC and the U.S. Attorney for the Southern District of New York to conduct a full investigation of the timing of Mr. Feuerstein's posts and their relationship to short seller financial interests.".....
"CREW's letter to the SEC also notes similar suspicious timing related to Mr. Feuerstein's reporting on drug companies GTx (GTXI) and Mannkind (MNKD). As GTx's stock reached near-record levels in July 2013, Mr. Feuerstein published an article predicting the failure of a critical drug trial, citing an unnamed short seller as a source. Mr. Feuerstein refused to correct the multiple errors in his article despite a point-by-point refutation by a GTx investor posted on seekingalpha.com. Similarly, in March 2014, Mr. Feuerstein published an article predicting a 60-percent chance the Food and Drug Administration (FDA) would reject the company's new drug, Afrezza. By the end of the day, Mannkind's shares were trading at a 10-month low. Contrary to Mr. Feurstein's prognostication, on April 1, an FDA advisory committee granted marketing approval for Afrezza by a vote of 13 to 1."
Naked Shorting and Bear Raids Attacks not only Delay Promising Drugs to Market it is a threat to U.S. Economy and National Security i.e. 9/11 and 2008 financial crisis
There is also overwhelming evidence Naked Shorting and Bear Raids are tools used not only by greedy wall street hedge funds etc. but by terrorists and it is a threat to U.S. economy and National Security as well as overall financial market.
Per SEC own admission of how naked shorting contributed to the 2008 economic meltdown and SEC actions taken against naked shorting during market crash.( See excepts below, Click titles for full story)
Wikipedia Naked Short Selling
"In 2008, SEC chairman Christopher Cox said that the SEC "has zero tolerance for abusive naked short-selling" while implementing new regulations to prohibit the practice, culminating in the September 2008 action following the failures of Bear Stearns and Lehman Brothers amidst speculation that naked short selling had played a contributory role."
SEC Enhances Investor Protections Against Naked Short Selling
"Washington, D.C., July 15, 2008 - The Securities and Exchange Commission today issued an emergency order to enhance investor protections against "naked" short selling in the securities of Fannie Mae (FNMA), Freddie Mac (FMCC), and primary dealers at commercial and investment banks."
Interesting to note this emergency order took place 2 months before the mortgage and bank stocks collapsed. This suggests naked short positions were well in place before the halt and funds still failed to deliver non existing shares. The Fed stepped in on behalf of Government Sponsored Agencies and SEC halted the naked shorting of Fannie Mae and Freddie Mac and the Banks but left all other companies vulnerable to naked shorting manipulation.
Most of the market shrugged it off until Sept 15th when Lehman Brothers declared bankruptcy. The funds like Goldman Sachs saw the writing on the wall and shorted some of these stocks heavily after selling the junk CDO's that were fraudulently rated AAA investments to the very companies Goldman Sachs shorted. Strangely enough Hank Paulson CEO of Goldman Sachs at the time was appointed in charge over which companies would receive portions of the $700 billion bailout funds.
Talk about putting the fox in charge of watching the hen house ! Anyone of us would be doing 20 years to life behind bars playing cards with Bernie Madoff. Instead some of the bail out recipients went to lavish resorts and used bail out funds to award themselves millions in bonuses for the job well done selling the worthless CDO's etc. while millions of Americans lost their life savings due to their swindle.
Stock Market Crash of 2008
"However, in July 2008 the subprime mortgage crisis had spread to government sponsored agencies Fannie Mae and Freddie Mac, requiring a Federal government bailout. The Treasury Department guaranteed $25 billion in their loans and bought shares of Fannie's and Freddie's stock, while the FHA to guaranteed $300 billion in new loans. The Dow closed on July 15 at 10,962.54, before bouncing back above 11,000 for the rest of the summer....."
"The month started with chilling news -- On Monday, September 15, 2008, Lehman Brothers declared bankruptcy. The Dow dropped 504.48 points."
There is substantial evidence that institutions not only naked short non existing shares but fail to deliver these shares that do not actually exist and an exemption was issued to Bernie Madoff before SEC finally shut his ponzi scheme down, nicknamed the Madoff Exemption.This article below reveals this exemption not only allowed him and other market makers to naked short stocks on a down tick but allowed them to rent out this exemption to other market makers. This article also shows naked shorting occurred from brokerages in London and Dubai by those renting this exemption and played a part in 2008 financial meltdown in an attempt to derail U.S Economy. ( See excerpts below, click link for full story )
Madoffs Crime of Staying Naked Short
“ "The Madoff exemption, for example, allowed market makers to naked short sell, presumably to facilitate liquidity. Unfortunately, due to naked sponsored access rules (pages 153-155 of Secret Weapon), this also meant that almost anyone could get an exemption at will... Madoff also obtained an exemption allowing market makers to sell short on a down-tick."
The 9/11 attacks also involved naked shorting and overall damage to our U.S. Economy according to some estimates was approximately $3.3 trillion.(See excerpts below, click title link for full story)
One 9/11 Tally: $3.3 Trillion - Interactive Feature
"Al Qaeda spent roughly half a million dollars to destroy the World Trade Center and cripple the Pentagon. What has been the cost to the United States? In a survey of estimates by The New York Times, the answer is $3.3 trillion, or about $7 million for every dollar Al Qaeda spent planning and executing the attacks."
That figure pales in comparison to the still growing cost of the 2008 financial meltdown estimated at $12.8 trillion which was more than the National debt $9.986 trillion in January 2009 when President Obama took office . The National debt is fast approaching $18 trillion at $17.946 trillion and growing at an alarming rate of approximately $2.45 billion per day with interest alone on this debt per day at approximately $1.2b which is about what Americans paid in State taxes in 2013. One has to wonder how State funded programs and facilities can stay afloat without major tax hikes when the current State taxes are about equal to the interest on the National Deficit. (See excerpts below , Click link for full story )
Cost of Financial Crisis Calculated at $12.8 Trillion ...
"Cost estimate is derived from two numbers. First, it includes estimates of losses to GDP for the period 2008 to 2018, based on estimates of the difference between actual GDP and projected values for the period had there been no financial or economic crisis. From 2008 to 2011, the difference between actual and potential GDP was $3.6 trillion. By 2018, the difference was forecast to widen to $7.6 trillion."
According to USADEBTCLOCK
"During President Obama's first two years in office, the U.S. government added more to the U.S. national debt than the first 100 U.S. Congresses combined."... For President Obama, the debt started at $9.986 trillion in January 2009 and increased to $13.7 trillion, a 38 percent increase over two years, by January 2011. By May 2011 it stood at $14.3 Trillion - $600 Billion in 4 months."
President Obama has 795 days left in office and with National Debt rising at $2.45b a day there will be another $1.947 trillion added to the current $17.946 totaling $19.893 + trillion. The interest rates are currently low but should the Fed need to raise interest rates the interest on this debt alone could eventually double and reach over $1 trillion a year. These figures clearly show how these financial terrorist attacks along with Wall Street irresponsible greed led to the 2008 financial crisis and combine to become a recipe for disaster and insurmountable debt. Both involved naked shorting as a tool that contributed to the derailing of U.S. economy and has put American's in a dire debt position making U.S. economy vulnerable should more attacks occur.
If facts and figures above are not worrisome enough a recent article reveals planned attacks on U.S. economy could be activated at any time. With the "trojan horse malware" mentioned in article believed to have been planted by "Russian hackers" thought to be tied to Russian Government. With current tensions between U.S. and Russia due to Ukraine circumstances the U.S. economy could suffer another 9/11 financial terrorist type attack which was estimated to have cost our economy up to $3.3 trillion.
See Nov 6th 2014 article 'Trojan Horse' Bug Lurking in Vital US Computers Since 2011
Many Hedge Funds Behind Naked Shorting are Greedy Bernie Madoff Like Individuals Running Well Funded Hedge Funds and Those like Cramer and Feuerstein Helping Them Profit with FUD ( Fear , Uncertainty and Doubt ) Bear Raid Attacks.
Our group Stop Naked Shorting acknowledges that the housing bubble popped due to subprime predatory loans and risky investment instruments such as derivatives and junk grade CDO's that were fraudulently stamped with AAA ratings were the main causes of 2008 financial meltdown. That said it was politicians whom approved the subprime loan agenda that paved the way for Wall Street greed to wipe out the 401k's of millions of Americans causing massive loss of jobs, forcing many into foreclosure. The evidence shows naked short selling and failure to deliver those non existent shares was a detrimental contributing factor that magnified the 2008 collapse and is still a threat to our financial markets, Economy and National Security today.
For sake of clarity, naked shorting has same effect as counterfeiting 100's of billions of dollar bills which devalues the value of the real currency. Just as U.S. Government printing $700 billion to bailout the Wall Street crooks who gambled away the investments of millions of Americans devalues the dollar and increases national debt. Failure to Deliver naked short shares has similar effects on stocks price per share as the counterfeit shares have added up to equal the amount or in some cases even more than the outstanding shares. ( Excerpts below for full article click link )
Naked Shorting The curious incident of the shares that didn't exist
"Systemic problem - The stock borrow program at the DTCC, they allege, enables the naked shorting of shares to the extent that the number of shares in circulation of some companies is now several times in excess of that issued. Even companies listed on the NYSE, could have been affected. As Wes Christian, partner in law firm Christian, Smith & Jewell in Houston, and lead lawyer on several of the cases, explains: "With the revelation of the Regulation SHO Threshold Securities list and the Leslie Boni report, published in November 2004 [see glossary], it is now crystal clear that this problem of naked short selling is systemic in Wall Street, and virtually impacts every business sector on every exchange including numerous billion-dollar companies listed on the NYSE and other companies listed on the Amex."
Burrell, who worked as an options trader before establishing himself as a consultant to small IT, healthcare, and generalist companies - the type that would be listed on the OTC bulletin boards - has researched the problem. His conservative estimate is that more than 1,000 companies presently have shares in circulation in excess of their floats, and that for at least 500 this number exceeds the number outstanding (the float plus shares that are not available on the market) - in some cases many times that number."
The SEC was negligent in their prior actions of making changes to the uptick rule via their " Madoff Exemption" and their dereliction of duty continues by not putting an end to naked shorting which could be done by SEC and NTCC implementing additional more stringent regulations and programs installed to prevent such trades from being executed. ( See previous petition by Investors4Justice )
Stop Naked Shorting is also preparing a petition to be submitted to petitions.whitehouse.gov to follow current petition which will require 25,000 signatures in 30 days in order to qualify for a response to be made by the White house. Current petition that supporters can sign will be sent to SEC & DTCC to let them know we mean business and to see how long it might take to gain 25000 signatures. Current petition can be read at thepetitionsite
Should the 2nd petition fail to bring an end to naked shorting then we propose a joint lawsuit be filed by as many publicly traded companies and shareholders, concerned citizens, investors, supporters as possible. This proposed lawsuit would be against all institutions and bear raid parties involved in naked shorting U.S. stocks as well as against the SEC / NTCC for failing to put a stop to this unfair manipulative practice. The SEC knows the threat it presents to National Security, U.S. Economy and Publicly traded companies & shareholders as their actions to 2008 financial crisis clearly demonstrated.
We also will propose a State by State Initiative against naked shorting be placed on ballots starting with New York to let American voters decide if naked shorting should be banned once and for all.
Thanks for reading this article and we hope you will to join in our effort to stop naked shorting. Please send us an email at Stopnakedshorting at yahoo to join our effort and to be updated when white house petition is submitted so we can reach the 25000 signatures in 30 days quota.
Disclosure: The author is long MNKD.
Additional disclosure: The author has found referenced info on the internet and believes the sources are accurate but cannot guarantee that all info is 100% correct. The author also has interjected his own opinions based on his perceptions of what he believes to be accurate and some may disagree with such opinions and perceptions. As always readers are recommended to do their own research and draw their own conclusions and are welcome to post them in comments to this article.
Themes: naked shorting, fails to deliver, economy, national security, 2008 financial crisis, financial terrorism Stocks: MNKD, DNDN, NWBO, SNY, GTXI, FNMA, FMCC
Back To VerticalView's Instablog HomePage »
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this Instablog with a colleague
0
Comments (3)
Track new comments
VerticalView
Comments (253) | + Follow | Send Message
Author’s reply » As usual Seeking Alpha made up excuses for opting to pass on this article to which I replied that this article was about the economy, overall financial markets and nation security and threat naked shorting poses to them and is not an investment thesis as they suggested . The multiple references they seemed to have an issue with as well though not original to the author are found in 100's of SA articles they publish on a regular basis. I told them this issue is much to important to not publish and asked them to spare me the excuses and for them to prove they are not naked short , Jim Cramer , Adam Feuerstein supporters by publishing this article. They declined to comment or publish the article.
18 Nov, 04:22 PM Reply
Like 2
12120341
Comments (97) | + Follow | Send Message
Thank you for this excellent article. Everyone needs to contact CREW to go after AF and Cramer. Both guys seem less than honest, to say the least. Anyone who has followed MNKD for a while can clearly see the manipulation.
18 Nov, 04:50 PM Reply
Like 0
kretikos
Comments (51) | + Follow | Send Message
Couldn't agree more. Those who engage in this practice are killing American jobs and innovation. They are common criminals who deserve everyones disdain.
18 Nov, 05:13 PM
|
|
|
Post by mnkdfan on Nov 19, 2014 13:35:50 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 19, 2014 13:45:08 GMT -5
Not negative? "Though the company is currently strong in diabetes, its pipeline doesn't reflect growth in the space, he said. " Really? Toujeo and Afrezza doesn't reflect growth ? Sounds pretty negative to me.
|
|
|
Post by mannmade on Nov 19, 2014 18:20:47 GMT -5
In case anyone forgets why they invested in Mannkind or the potential market size...
As a nation, our sugar addiction is catching up with us — yet many of us are still unaware the stuff is wreaking havoc inside our bodies. (Getty Images)
You’d think a disease that can cause blindness, leads to amputations, and is the 7th leading cause of death in the United States would incite mass panic.
Yet Americans — and even some doctors — don’t take diabetes very seriously. (Did you even know it’s American Diabetes Month?) “Sometimes, people think ‘serious’ means things that kill you right away,” said Dr. Carlos del Rio, chair of the Emory University Department of Global Health. “But, the reality is, I would be more concerned about diabetes than Ebola.”
This lax attitude toward the disease may explain why nearly 30 percent of Americans who have diabetes don’t realize it, according to a new study in the Annals of Internal Medicine, conducted by Del Rio and other Emory University scientists. They analyzed health data for 29,353 people from the National Health and Nutritional Examination Survey, identifying those with diabetes based on levels of fasting glucose and hemoglobin A1C (an indicator of blood-sugar control).
Overall, about 12 percent of all U.S. adults had diabetes, which translated to 28.4 million people in 2012. Among those, nearly 8 million hadn’t been diagnosed — a stat that’s made all the more alarming by the fact that most regularly went to the doctor: Two-thirds of undiagnosed diabetics had seen a health care provider at least twice in the past year, the study found.
Related: The Sneaky Cause of Your Sugar Cravings
Going undiagnosed — or even just delaying the process — is asking for internal trouble. The longer diabetes goes untreated, the worse the outcome tends to be. “Once the disease sets in, it’s really progressive,” study co-author Mohammed Ali, an assistant professor of global health at Emory University, told Yahoo Health. “It may be slow in some cases, but it leads to really disabling and often fatal complications.” Common but scary outcomes include vascular disease, kidney disease, or eye disease, which can lead to blindness.
On the flip side, if you catch and control diabetes early, “patients are very likely to do well, in terms of delaying the onset of all these horrendous complications, preserving their quality of life,” said Ali.
Unfortunately, the nature of the disease means that patients who should be undergoing blood tests often slip through the cracks: Diabetes is typically asymptomatic until people develop serious complications, so doctors don’t necessarily have clear cues to prompt them to suggest testing early on (although weight, family history, and lifestyle should be a consideration). “Diabetes is the silent killer,” said Del Rio.
And because the U.S. is a nation of episodic care — that is, we seek medical attention for specific symptoms, rather than as a matter of routine — doctors aren’t necessarily thinking about performing preemptive blood tests on high-risk people. Instead, they’re usually focusing on, say, the patient’s back-pain problem, and not his or her overall care.
However, doctors are only one part of the equation: Patients may not be proactive about seeking care, Ali said, perhaps as a result of a low perceived risk of diabetes, poor insurance coverage, or even just time constraints. In the study, young people (ages 18 to 44) were especially likely to go undiagnosed, probably because they only seek care if they feel sick. “With diabetes, you don’t feel bad per se,” said Ali. “There’s a whole lot going on inside you, but you don’t feel it.”
Even after patients are diagnosed, they aren’t necessarily controlling their diabetes, either. “We may not link them to care properly or maintain them in care,” said Del Rio. “It’s a whole cascade of care issue.” In the study, only about 1 in 5 diagnosed diabetics refrained from smoking and had achieved the targets for hemoglobin A1C, blood pressure, and LDL “bad” cholesterol.
Related: Young, Fit…and Diabetic
An estimated 75 percent of those with known diabetes also had high blood pressure. “It’s a double whammy,” Del Rio said. “High blood pressure impacts your blood vessels, and diabetes impacts your blood vessels. And it’s blood vessel disease that leads to stroke and heart disease.” In fact, diabetics are 1.5 times time more likely to be hospitalized for a stroke and about 1.7 times more likely to die of heart disease than people without the disease, according to the American Diabetes Association.
“Basically, the guidelines say, ‘Don’t just focus on sugar,’” said Ali. “Do the whole ABCD: the A1C is the sugar measurement that we use, B is blood pressure, C is cholesterol, and D is do not smoke.”
So how can our health care system ensure diabetes is caught, as well as treated? The first step: Increasing the emphasis on primary care, so patients regularly see doctors who monitor their weight, cholesterol, blood sugar, and vital signs, while also assessing their family history. “Chronic diseases are not controlled by episodic care,” said Del Rio. “You need to have somebody that monitors you regularly.”
And patients who are diagnosed shouldn’t be shy about voicing their concerns about the prescribed treatments — for example, side effects of diabetes drugs or a lack of time to exercise. That way, doctors can help devise solutions that patients are more likely to comply with.
It’s not entirely up to the patient to halt diabetes in its tracks, though. “We need to start focusing on [figuring out] the interventions we need to do in order to improve outcomes,” Del Rio said. “I envision doing more testing, and not only in the health care settings.” He sees workplaces, community centers, churches, and even local fairs as potential diabetes testing sites, and once people are flagged for the disease, he believes insurance companies should consider getting involved.
“We could work with insurance providers to ensure people are actually getting their medications and not falling out of care,” said Del Rio. “Because, at the end of the day, if we don’t pay for care now, we’re going to pay for care later when they develop renal disease and other complications.”
|
|
|
Post by dreamboatcruise on Nov 20, 2014 19:11:09 GMT -5
|
|
|
Post by mannmade on Nov 20, 2014 19:40:54 GMT -5
Yes but he really did not mention any one product to promote (only one or two were referenced to make his point about diversity of product categories and launches) Looks like Sanofi is looking to grow both with it's strength in diabetes (it's traditional core strength) and outside diabetes.
|
|
|
Post by brentie on Nov 21, 2014 17:37:48 GMT -5
|
|
|
Post by kc on Nov 22, 2014 10:25:28 GMT -5
A new positive article in Barrons . m.barrons.com/articles/BL-SWB-35588MannKind’s Afrezza Remains in Sanofi’s Plans, RBC Says By Ben Levisohn Yesterday, Sanofi hosted a seminar on new medicines in Cambridge, Mass., and RBC’s Adnan Butt and team note that MannKind’s (MNKD) inhaled insulin Afrezza “featured prominently enough.” They summarize the highlights of the presentation: Reuters MannKind’s partner reiterated prior guidance that a commercial launch is planned for 1Q:15. Some had feared this timing could be retracted. In terms of pricing, Sanofi underscored that the benchmark could be rapid acting, injectable insulin, which is in line with our forecasts… Focus on patients driving demand also important. As part of launch prep, Sanofi has conducted patient preference studies which show 60% of those starting insulin and 57% of those who need more insulin liking Afrezza’s profile. The market opportunity could be meaningful given 66% of patients resist moving to injected insulin with the period of resistance being ~5 years. Patients described as the initial candidates for Afrezza include those who are on two or more oral agents and resisting moving on to injectable insulin and those who need meal-time insulin, where combined patient populations could be ~3M. Even adjusting for smokers or those with pulmonary disorders shows the opportunity remains sizable but where greater Street confidence could require execution for a few quarters post launch. Among other highlights: Sanofi demonstrated how much easier Mannkind’s Afrezza is to use compared to Pfizer’s (PFE) infamous flop Exubera, Butt said, and that Sanofi was in negotiations with the FDA over post-approval studies that could expand Afrezza’s use. I am sure analyst will start following the stock with upgrades in 2015. The will all be bulls like Butts at RBC.
|
|